iSonea Limited Announces Publication of Initial Viriathus Research Report

SEVERNA PARK, Md.--()--iSonea Ltd. (ASX:ISN);(OTCQX:ISOAY), an emerging medical technology company developing innovative monitoring systems and software for the management of asthma, today announced that Viriathus Research LLC has issued an initial informational research report on the Company. iSonea’s American Depositary Receipts (ADRs) began trading today on the OTCQX marketplace in the U.S. under the symbol ISOAY.

The report outlines the Company’s

  • Commercial strategy for development and launch of the first Acoustic Respiratory Monitoring devices that allow anyone to monitor breathing symptoms anywhere, at anytime;
  • Enormous opportunity to address unmet needs in the rapidly growing asthma market, both in the U.S. and worldwide;
  • New management team with successful track record of growing innovative medical technology companies.

“We are pleased to see the publication of this report by Viriathus, which will help to increase the visibility of our opportunity to investors focused on novel medical and mobile health technology,” said Michael J. Thomas, Chief Executive Officer.

Interested parties may download a copy of the Viriathus Research report on iSonea by accessing the Viriathus Research archive at www.viriathus.com.

About iSonea Limited

iSonea Limited (formerly KarmelSonix) is an emerging medical technology company developing innovative, non-invasive Acoustic Respiratory Monitoring™ (ARM) devices and software for the management of asthma and related pulmonary disorders. ARM is a breakthrough in asthma management. ARM devices are more patient-friendly than traditional tests, addressing a huge unmet medical need for frequent asthma monitoring, which is routinely recommended to improve asthma control. iSonea’s ARM technology makes accurate, consistent, frequent monitoring possible for any patient, anywhere, at any time. iSonea’s ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. Specific ARM devices have been designed for intermittent or continuous monitoring applications in clinical settings and for consumer use in life settings.

About Viriathus Research LLC

Viriathus Research LLC is a quality-leading independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutional investors that invest in them. For further information on Viriathus Research please visit www.viriathus.com.

Contacts

iSonea Limited
Mr. Michael Thomas, +1-410-777-5251
Chief Executive Officer
mthomas@iSoneaMed.com
www.iSoneaMed.com
or
Schwartz MSL Boston
Helen Shik or Jennifer Netzband, +1-781-684-0770
iSonea@schwartzmsl.com
www.schwartzmsl.com

Release Summary

iSonea Ltd. an emerging medical technology company developing innovative monitoring systems & software for asthma management, today announced that Viriathus Research issued an initial research report.

Contacts

iSonea Limited
Mr. Michael Thomas, +1-410-777-5251
Chief Executive Officer
mthomas@iSoneaMed.com
www.iSoneaMed.com
or
Schwartz MSL Boston
Helen Shik or Jennifer Netzband, +1-781-684-0770
iSonea@schwartzmsl.com
www.schwartzmsl.com